As a tyrosine kinase, FLT3 represents an attractive therapeutic target, and the therapeutic effects of inhibiting FLT3 have been explored in leukemia, particularly in AML with FLT3 ITD7,22,28–33. The gene discussed is FLT3; the disease is acute myeloid leukemia.